DSIP

DSIP (Delta Sleep-Inducing Peptide) is a synthetic nonapeptide with the sequence Trp-Ala-Gly-Gly-Asp-Ala-Ser-Gly-Glu. It was originally isolated from the cerebral venous blood of rabbits during induced sleep by Marcel Monnier and Guido Schoenenberger at the University of Basel in 1977.

The original isolation was a classic experiment in transferable sleep factors. Rabbits induced into sleep by low-frequency electrical stimulation of the thalamus generated cerebral venous blood with sleep-inducing activity. When this blood was perfused into recipient rabbits, the recipients exhibited increased delta-wave activity in their EEGs.

The compound has no commercial pharmaceutical development history of consequence. No major pharmaceutical company has pursued DSIP through formal regulatory trials. The clinical literature is dominated by small Russian and Eastern European studies in the 1980s and 1990s. The Western evidence base is essentially absent.

The Human Evidence Base

Human clinical-trial data on DSIP is limited and largely from Russian and Eastern European publications. Small open-label and limited randomized trials in patients with chronic insomnia have reported subjective sleep improvement. The trials are generally small (under 50 patients), short-duration, and often lack placebo control. The compound has not undergone a properly powered, placebo-controlled, polysomnographically monitored Phase 2 trial that would meet Western regulatory expectations.

The mechanism of DSIP remains incompletely characterized despite 50 years of investigation. Proposed mechanisms include modulation of GHRH and corticotropin secretion, interactions with endogenous opioid systems, direct effects on hypothalamic sleep nuclei, and broader anti-stress and adaptogenic effects.

The major problem with the DSIP mechanism literature is that no clean, well-characterized molecular target has emerged. Unlike GLP-1 agonists (clear receptor binding) or melatonin (clear receptor signaling), DSIP's mechanism remains broadly described and hard to verify with modern pharmacological tools.

Regulatory status

No major regulatory approval. DSIP has no FDA approval, no EMA approval, no MHRA approval, no Health Canada approval, and no marketing authorization in any major regulatory jurisdiction.

The peptide is not currently on the FDA Category 2 bulks list under Section 503A as of May 2026. Compounding pharmacy availability has historically been limited.

The compound is widely sold by online research-chemical vendors with "for laboratory use only" labeling. Quality control on these products is variable.

WADA status. DSIP is not currently on the WADA Prohibited List.

Original Schoenenberger Protocols (1970s-1980s)

The earliest DSIP dosing comes from the Schoenenberger group at the University of Basel and from later Swiss and Eastern European replication work.

IV administration: 25 to 50 nmol/kg intravenously, typically as a single dose 30 to 60 minutes before bedtime. For a 75 kg adult, 25 nmol/kg corresponds to approximately 1.6 mg (based on a molecular weight of approximately 850 Da). The IV route is the only route with published Schoenenberger group efficacy data, though the magnitude of effect even in those small studies was modest.

Schneider-Helmert and Schoenenberger 1983 trial: Tested DSIP in insomniacs at the IV doses described above. Results were mixed, with some subjective sleep improvement but no clear effect on polysomnographic measures.

Modern Adult Off-Label Compounded Protocols

The dosing pattern used in current research-chemical contexts diverges from the original Schoenenberger protocols.

Standard adult research protocol: 100 to 300 mcg administered subcutaneously 30 to 60 minutes before bed. The dose is not weight-adjusted. The 200 mcg dose is the most commonly reported in adult sleep-optimization contexts.

Higher dose protocols: 500 to 1,000 mcg per dose are used in some research-chemical settings, though there is no published evidence supporting these higher doses.

Cycling pattern: Most protocols use 5 to 10 nights of consecutive use followed by 1 to 2 weeks treatment-free, then repeated as needed. The rationale is theoretical rather than evidence-based.

None of the modern compounded protocols has been validated in a randomized controlled human trial.

Pharmacokinetics

DSIP has a plasma half-life of approximately 5 to 10 minutes after intravenous administration. This is among the shortest plasma half-lives of any peptide in adult research use. The brief plasma exposure has been used to argue against the molecule's clinical usefulness, since most receptor-mediated drug effects require sustained plasma concentrations.

The compound is metabolized through rapid plasma proteolysis. Renal and hepatic clearance pathways are not clinically significant given the short plasma half-life and rapid degradation.

Administration Routes

Subcutaneous injection is the most common route in adult off-label use. Injection sites include the abdomen, thigh, or upper arm.

Intravenous administration was the original Schoenenberger route. Not used in adult off-label settings due to inconvenience.

Intranasal administration has been described in some Russian sleep medicine publications. The peptide is small enough to potentially achieve some nasal absorption. Bioavailability and dose equivalence have not been characterized in Western publications.

Oral administration is not viable due to rapid gastric peptidase degradation of the small peptide.

Reconstitution

DSIP is typically supplied as lyophilized powder in 2 to 10 mg vials. Reconstitution uses bacteriostatic water at convenient working concentrations. A 2 mg vial reconstituted with 2 mL yields 1 mg/mL solution; a 200 mcg dose delivers in 0.2 mL.

Why DSIP Dosing Is Not Validated

The DSIP dosing protocols used in modern adult settings have not been validated in any randomized human dose-finding trial. The original Schoenenberger protocols used IV administration at doses that translate to approximately 1.5 to 3 mg in a 75 kg adult, considerably higher than the 100 to 300 mcg used in modern subcutaneous settings. Adult DSIP dosing is empirical rather than evidence-based.

The DSIP safety database is largely descriptive and uncontrolled. Reported adverse events include mild fatigue or grogginess the morning after administration, vivid dreams, occasional headache, and mild gastrointestinal effects. No serious systemic toxicity has been reported in the small published clinical literature.

The major safety limitation is the absence of long-term randomized safety data. The compound has not been studied at the duration or sample size needed to characterize chronic safety. The unregulated supply chain creates additional safety considerations independent of the compound itself.

Melatonin and melatonin agonists (ramelteon, tasimelteon) are well-characterized sleep agents with substantial trial data. Ramelteon is FDA-approved for insomnia. These are the established sleep peptide alternatives with proper evidence backing.

Orexin receptor antagonists (suvorexant, lemborexant) are newer sleep agents with strong Phase 3 trial backing.

Behavioral sleep interventions (CBT-I) are first-line for chronic insomnia in most guidelines.

For chronic insomnia, DSIP is not a competitive option compared with FDA-approved alternatives.

For informational and educational purposes only. Not medical advice.